Beijing Hotgen Biotech Co., Ltd. engages in the research, development, manufacture, and sale of medical and public safety inspection products of in-vitro diagnostic products in the field of biomedicine. It offers nucleic acid drugs, antibody drugs, and biotechnology health and beauty consumer products. The company also provides clinical diagnostics and product solutions, including Upconversion light, chemiluminescence, sugar capture, microfluidics, and genetic testing for testing of intestinal microorganisms, gastrointestinal foodborne infections, insect-borne diseases, respiratory pathogens, infectious diseases, Ebola virus antigen, biological warfare agents, microorganisms, and mycotoxins. Beijing Hotgen Biotech Co., Ltd. was founded in 2005 and is based in Beijing, China.
Country
Sector
Themes
Also in
Price· split & dividend adjusted
No price history for this asset yet.
News & notes moving688068.CG
688068.CG▼
Rejing Bio's first-half net loss widens to 126 million yuan
Rejing Bio released its 2026 half-year report on August 26. First-half operating revenue was 268 million yuan, up 31.3 percent year on year, but net profit attributable to the parent swung from a loss of 82.74 million yuan a year earlier to a loss of 126 million yuan. Net profit attributable to the parent after deducting non-recurring items was a loss of 144 million yuan, and net operating cash flow was negative 112 million yuan, down 743.2 percent year on year. Second-quarter revenue was 152 million yuan, up 37.1 percent year on year. The net loss attributable to the parent was 58.07 million yuan, narrower than the 59.99 million yuan loss a year earlier, but the loss after deducting non-recurring items widened to 67.75 million yuan. As of the end of the second quarter, total assets were 3.064 billion yuan, down 3.7 percent from the end of the previous year, and net assets attributable to the parent were 2.442 billion yuan, down 1.8 percent. During the reporting period, revenue from the company's C-series large chemiluminescence platform products in its in vitro diagnostics business continued to grow, and revenue from biotechnology consumer products rose significantly. The company also accelerated its push into innovative biologic drugs, focusing on the development of the therapeutic antibody SGC001 for acute myocardial infarction and the antibody drug AA001 for Alzheimer's disease, with clinical progress showing good safety and preliminary efficacy. The company is also actively expanding three major health initiatives covering liver health, brain health, and early cancer screening and diagnosis for the Chinese population, building a full-scenario innovative diagnostic technology platform.
Hotgen Biotech Completes 50.02 Million Yuan Share Buyback
Hotgen Biotech announced that as of July 31, 2026, it had repurchased 580,000 shares, accounting for 0.63% of total share capital, with a total repurchase amount of 50.02 million yuan and a repurchase price range of 79.25 yuan to 91.06 yuan per share. In the first quarter of 2026, the company achieved revenue of 116 million yuan and a net loss attributable to the parent company of 68.06 million yuan.
Hotgen Biotech Subsidiary's Innovative Drug SGC001 Injection Receives Clinical Trial Approval for New Indication
Hotgen Biotech announced that its subsidiary Shun Jing Pharmaceutical has received a Drug Clinical Trial Approval Notice issued by the National Medical Products Administration. The clinical trial application for the innovative drug SGC001 injection for a new indication, anticipated severe acute pancreatitis, has been approved. The drug previously received clinical approvals from the U.S. FDA and China's CDE, and was granted Fast Track designation by the FDA. The Phase II clinical trial is currently progressing smoothly.
Innovative drug industry chain shines as Sci-Tech Innovation Board Healthcare ETF Huaxia sees active trading
As of 2:45 p.m. on July 22, 2026, constituents of the SSE STAR Board Biomedical Index were mixed. BrightGene led gains with 12.20%, Medicilon rose 5.98%, Bloomage Biotechnology gained 5.40%, while Hotgen Biotech led declines. The Sci-Tech Innovation Board Healthcare ETF Huaxia last traded at 1.05 yuan, with intraday turnover of 15.98% and turnover of 61.5624 million yuan. Average daily turnover over the past week was 77.0437 million yuan. In news, as of July 20, 94 of the 504 A-share pharmaceutical and biotech companies had disclosed earnings forecasts, a disclosure rate of 18.65%. Among them, 55 companies reported positive net profit growth for the first half of the year, accounting for 58.51%. The innovative drug industry chain and the CXO sector performed notably well. Tianfeng Securities pointed out that in the first half of 2026, there were 621 global transactions, of which 90 involved Chinese molecules, accounting for 14.5%. The total global transaction value reached 302.893 billion US dollars, of which Chinese molecules accounted for 95.905 billion US dollars, or 31.66%. The influence of Chinese innovative molecules is steadily growing worldwide. The Sci-Tech Innovation Board Healthcare ETF Huaxia closely tracks the SSE STAR Board Biomedical Index, which selects 50 listed companies in the biomedical and related fields with larger market capitalizations from the STAR Board as samples. The top ten weighted stocks account for a combined 51.84%.
Pharmaceutical sector surges across the board, STAR Market Healthcare ETF Huaxia jumps over 5.6%
The pharmaceutical sector surged across the board, with the STAR Market Healthcare ETF Huaxia rising 5.61% to a latest price of 1.11 yuan. As of 11:23 on July 15, 2026, the SSE STAR Market Biomedical Index rallied 5.60%, with constituents Borui Pharma and Dizal Pharmaceutical both up 20.01%, and Hotgen Biotech up 12.64%. The healthcare industry has recently seen multiple policy catalysts, including the 15th Five-Year Plan for National Health proposing decisive progress in building a Healthy China by 2030, the National Health Commission and other ministries issuing new rules on centralized procurement of medical equipment, and the official implementation of the 2026 National Essential Medicines List. Guosheng Securities noted that in the first half of 2026, the total value of overseas licensing deals for domestic innovative drugs reached 99.7 billion US dollars, with Chinese projects accounting for eight of the world's top ten licensing deals. The STAR Market Healthcare ETF Huaxia closely tracks the SSE STAR Market Biomedical Index, which selects 50 larger market-cap listed securities in the biomedical sector on the STAR Market as constituents, with the top ten holdings accounting for 51.84% of the total weight.
Innovative drug valuations recover, Sci-Tech Innovation Board Medical ETF Huaxia rises nearly 1%
The Sci-Tech Innovation Board Medical ETF Huaxia rose 0.83%, heading for a sixth consecutive gain, with the latest price at 1.1 yuan. The Shanghai Sci-Tech Innovation Board Biomedical Index advanced 0.89%, with constituent Hotgen Biotech surging 10.60% and Mabwell Biotech climbing 9.42%. The National Medical Products Administration plans to include eligible cell and gene therapy drugs in a 30-day review channel for innovative drug clinical trial approvals, a policy that is catalyzing a valuation recovery for innovative drugs. The ETF has seen net inflows for six consecutive days, attracting a total of 61.04 million yuan.
Pharmaceutical Stocks Surge: Shouyao Holdings and Gan & Lee Pharmaceuticals Hit Daily Limit Up
The pharmaceutical sector rallied strongly during trading on the 6th, with weight-loss drug and innovative drug concepts standing out. Shouyao Holdings and Gan & Lee Pharmaceuticals were among multiple stocks that hit their daily limit up. As of press time, Shouyao Holdings surged by the 20 percent daily limit, Hotgen Biotech rose about 14 percent, Mabwell Bioscience, InventisBio, and Shanghai Yizhong Pharmaceutical gained over 10 percent, Gan & Lee Pharmaceuticals, Huahai Pharmaceutical, and Menovo Pharmaceutical also hit their daily limit up, BeiGene and Pharmaron climbed over 7 percent, and Hengrui Medicine advanced more than 5 percent. In the Hong Kong market, Duality Biologics, InnoCare Pharma, and Sino Biopharmaceutical rose over 10 percent, while WuXi XDC and Pharmaron gained more than 5 percent. On the news front, the National Medical Products Administration is soliciting public comments on optimizing the review and approval of cell and gene therapy drugs, encouraging clinically value-oriented R&D innovation, focusing on key areas such as malignant tumors and rare diseases, and placing eligible drugs into a 30-day review and approval pathway. Meanwhile, the overseas expansion of innovative drugs is accelerating. Since 2026, the total value of China's innovative drug license-out deals has reached 94.3 billion US dollars, up 81 percent year-on-year, with upfront payments reaching 5.5 billion US dollars, up 124 percent year-on-year, reflecting growing overseas recognition of China's innovative drug pipeline. CICC noted that leading innovative drug companies are shifting from the R&D investment phase into a positive cycle of commercial scale-up and overseas licensing revenue realization.
Precious Metals and Nonferrous Metals Concept Stocks Active, Baiyin Nonferrous and Others Hit Limit Up
In early trading on July 6, the three major A-share indices opened collectively higher, with the Shanghai Composite Index up 0.30%, the Shenzhen Component Index up 0.65%, and the ChiNext Index up 0.57%. Precious metals concept stocks rose rapidly, with Hunan Silver, Shanjin International, and Chifeng Gold among the top gainers. Nonferrous metals concept stocks were active, with Baiyin Nonferrous, Huanghe Whirlwind, and Yongshan Lithium hitting limit up. The innovative drug sector was also active, with Sanyuan Gene and Hotgen Biotech surging over 10%, after the National Medical Products Administration sought public comment on optimizing the review and approval of cell and gene therapy drugs, proposing to include eligible drugs in a 30-day review channel. JPMorgan expects gold to remain range-bound in the short term before rebounding, with an average price of 4,300 US dollars per ounce in the third quarter of 2026 and 4,500 US dollars per ounce in the fourth quarter, maintaining a long-term bullish view.
STAR Market Healthcare ETF Huaxia Gains Nearly 3%; Hotgen Biotech Establishes AI Drug Company
The STAR Market Healthcare ETF Huaxia closed up 2.93 percent, marking a five-day winning streak, with the latest price at 1.09 yuan. The SSE STAR Market Biomedical Index rose strongly by 3.21 percent. Among its constituents, MGI Tech surged 13.64 percent, Hotgen Biotech gained 11.62 percent, and Dizal Pharmaceutical advanced 11.12 percent. In related news, Hotgen Biotech has officially registered and established Beijing Entropy Intelligence Pharmaceutical Technology Company, signaling the phased implementation of its AI-driven drug R&D strategy launched in 2023, and it will continue to increase investment in AI technology for innovative drug business. The STAR Market Healthcare ETF Huaxia has seen net capital inflows for five consecutive days, attracting a total of 57.85 million yuan.